Personalis (PSNL) said Tuesday its two blood collection kits have received European regulatory approval under the EU In Vitro Diagnostic Regulation.
The company said the approval allows its EDTA Blood Collection Kit and cfDNA Blood Collection Kit to be used in clinical studies across the EU and Great Britain.
The kits are designed to preserve blood sample quality for advanced genomic testing, including detection of minimal residual disease using its NeXT Personal test, it added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments